

## EUCAST Steering Committee Meeting

### Summary of minutes of meeting in Berlin, Germany, 30-31 January 2006

#### Attending

Dr Derek F.J. Brown	DB	Scientific Secretary	United Kingdom
Dr Gunnar Kahlmeter	GK	Chairperson	Sweden
Dr Johan W. Mouton	JM	CRG	The Netherlands
Dr Inga Odenholt	IO	SRGA	Sweden
Prof Arne Rodloff	AR	DIN	Germany
Prof Claude-James Soussy	C-JS	SFM	France
Dr Martin Steinbakk	MS	NWGA	Norway
Dr Olga Stetsiouk	OS	EUCAST	Russia

#### Apologies

Dr Fred Goldstein	FG	SFM	France
Prof Alasdair P. MacGowan	AM	BSAC	United Kingdom
Dr Francisco Soriano	FS	EUCAST	Spain

<b>1</b>	<p><b>Chairman's welcome</b> C-JS represented SFM in place of FG. IO was welcomed as the new SRGA representative.</p>
<b>2</b>	<p><b>Minutes of meeting of 21-23 November 2005</b> With minor corrections the minutes were accepted as a correct record.</p>
<b>3</b>	<p><b>Matters arising from minutes of 21-23 November 2005</b> References are to be added for cefotaxime/ceftriaxone breakpoints for pneumococci from central nervous system infections.</p> <p>Expert groups have been consulted on cephalosporin breakpoints.</p> <p>A possible CEN/ISO document on methods for fungi is to be investigated.</p> <p>The daptomycin rationale document has been sent to the Steering Committee for checking.</p> <p>A note has been added to the breakpoint tables indicating links to rationale documents.</p> <p>The EUCAST discussion document on mycobacteria is being updated and the possibility of updating the cell-associated pathogens document is being investigated.</p> <p>The fluconazole rationale document is currently being worked on.</p> <p>Glycopeptide breakpoints for staphylococci are being reviewed.</p> <p>The EUCAST website will be updated before ECCMID, April 2006.</p> <p>Proposed EUCAST breakpoints for a new tetracycline have been sent to the EMEA.</p> <p>The agreed format for presentation of breakpoints in tables when resistance is unknown or very rare has been applied to all tables.</p> <p>Published evidence of clinical response with cefepime in infections with ESBL-producers with MICs of 2-8 mg/L is being sought.</p> <p>Proposed cephalosporin breakpoints are to be examined by National Committees.</p> <p>Dosages used to calculate EUCAST breakpoints will be included in rationale documents.</p>

Data in MIC distributions for  $\beta$ -lactam inhibitor combinations will be separated the basis of whether fixed inhibitor concentrations or ratios were used.

CLSI data have been added to penicillin rationale documents.

Linezolid, quinolone, aminoglycoside and glycopeptide rationale documents are being completed.

A table of oral beta-lactams used in different countries has been prepared.

**4 ESCMID Board Meeting**

The ESCMID board strongly supported current EUCAST progress and activities. The board has agreed to add another member to the Steering Committee to provide scientific support.

**5 CLSI meeting, Miami 21-24 January 2006**

A group has been set up to revise document M23 detailing data required for setting and changing breakpoints. It was suggested by some that this revision would be better done as an international document.

The Enterobacteriaceae working group has been suspended.

The discussion between CLSI and FDA over who has authority to set breakpoints continues.

EUCAST members also attended sessions on antifungal agents, trailing endpoints for linezolid and cefoxitin testing with staphylococci, and a communications working group.

**6 Discussions with other groups**

The European Veterinary Committee on Antimicrobial Susceptibility Testing (VETCAST) were working on the basis of epidemiological cut-off values.

**7 New drugs**

Three drugs are to be brought through EMEA this year.

**8 Daptomycin**

A satisfactory method is still to be devised for disc diffusion testing. The agent has been licensed for Vitek and Phoenix.

**9 EUCAST and Clinical Microbiology and Infection**

ESCMID will fund EUCAST technical notes on breakpoints in CMI. There will be a leading article in CMI introducing the technical notes.

**10 EUCAST Subcommittee on expert rules**

Expert members had been proposed and the subcommittee chairman, Roland Leclercq, would be asked to proceed with this as soon as possible.

**11 New tetracycline**

Final approval from EMEA is awaited.

**12 Consultation with national committees on breakpoints for cephalosporins, carbapenems and aztreonam**

Final comments are expected before the meeting in Nice on 31 March 2006.

The significance of AmpC for ertapenem breakpoints and low-level resistance to cefotaxime in Enterobacteriaceae were discussed.

**13 Intravenous penicillin breakpoints**

Basic data in rationale documents was reviewed and corrected and, following a preliminary review of data, tentative breakpoints for discussion were suggested.

<b>14</b>	<b>Formatting of rationale documents</b> Details of formatting of rationale documents were agreed.
<b>15</b>	<b>Version numbers in breakpoint tables</b> Agreed to put version numbers in a table below the breakpoint table.
<b>16</b>	<b>CEN/ISO</b> The MIC document is about to be distributed for final international vote. The document on assessment of in vitro devices is about to be issued for first vote.
<b>17</b>	<b>EUCAST symposium at ECCMID, Nice</b> The symposium is scheduled for the afternoon of Tuesday April 4 2006.
<b>18</b>	<b>EUCAST workshop at ECCMID, Nice, 1 April 2006</b> A programme on the need for speciation in susceptibility testing was agreed.
<b>19</b>	<b>CA-SFM method for glycopeptide susceptibility testing of enterococci</b> The CA-SFM recommendations to ensure detection of resistance in strains where expression was delayed were presented.
<b>20</b>	<b>Any other business</b> The new General Committee representatives after April 2006 will be Pietro Varaldo (Italy) and Waleria Hryniewicz (Poland).
<b>21</b>	<b>Next meetings</b>
21.1	30-31 March 2006, Nice. Preceding ECCMID meeting
21.2	12-13 June 2006. Copenhagen.
21.3	11-12 September 2006. Venue to be decided.
21.4	20-21 November 2006. Venue to be decided

Summary of ratified minutes of meeting 30-31 January 2006 prepared by DB and GK